Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Capital Expenditures: 2023-2025

Historic Capital Expenditures for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Sep 2025 value amounting to $42,000.

  • NewAmsterdam Pharma Co N.V's Capital Expenditures fell 44.00% to $42,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $149,000, marking a year-over-year decrease of 77.83%. This contributed to the annual value of $672,000 for FY2024, which is 2700.00% up from last year.
  • NewAmsterdam Pharma Co N.V's Capital Expenditures amounted to $42,000 in Q3 2025, which was down 52.27% from $88,000 recorded in Q2 2025.
  • NewAmsterdam Pharma Co N.V's Capital Expenditures' 5-year high stood at $385,000 during Q1 2024, with a 5-year trough of $3,000 in Q4 2023.
  • Its 3-year average for Capital Expenditures is $76,545, with a median of $16,000 in 2025.
  • Its Capital Expenditures has fluctuated over the past 5 years, first surged by 5,400.00% in 2024, then slumped by 95.84% in 2025.
  • NewAmsterdam Pharma Co N.V's Capital Expenditures (Quarterly) stood at $3,000 in 2023, then remained steady at $3,000 in 2024, then plummeted by 44.00% to $42,000 in 2025.
  • Its Capital Expenditures was $42,000 in Q3 2025, compared to $88,000 in Q2 2025 and $16,000 in Q1 2025.